Aug 2026· Journal of Cardiovascular Medicine· Vol 27 9, pp.
726-734
· 1 citation· 36 references
Medicine
TL;DR
Elderly patients were at higher risk of NACE, driven by an increased risk of both ischemic and bleeding events, the latter including access-site and nonaccess-site hemorrhages of both minor and major severity.
Abstract
BACKGROUND/
Objectives
We aimed to assess the clinical characteristics and in-hospital outcomes of elderly vs. nonelderly patients treated with cangrelor during percutaneous coronary intervention (PCI).
Methods
Patients undergoing PCI with cangrelor between January 2019 and May 2023 in seven Italian institutions were retrospectively enrolled. Patients aged ≥75 years at the time of PCI were classified as elderly. The primary endpoint was net adverse clinical events (NACE), a composite of cardiovascular death, myocardial infarction, stroke, definite or probable stent thrombosis, and Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding, evaluated at 48 h post-PCI. The impact of advanced age (≥75 years) on clinical outcomes was assessed using multivariable logistic regression (LR), inverse probability of treatment weighting (IPTW), and doubly robust (DR) models.
Results
A total of 1071 patients were included, of whom 340 (32%) were elderly. At 48 h, elderly patients had higher odds of NACE [odds ratio (OR) 2.11, 95% confidence interval (CI) 1.12-3.97, P = 0.021 by multivariable LR; OR 1.98, 95% CI 1.45-2.27, P < 0.001 with IPTW; and OR 2.09, 95% CI 1.51-2.93, P < 0.001 by DR estimation]. These results were driven by an increased risk of both ischemic and bleeding events, the latter including access-site and nonaccess-site hemorrhages of both minor and major severity.
Conclusions
In this real-world study of patients undergoing PCI with cangrelor, elderly individuals accounted for one-third of the population. Elderly patients were at higher risk of NACE, driven by both ischemic and bleeding events.
PCI with drug-eluting stents for ULMCAD was safe and effective, with favorable long-term outcomes in patients who were unfit for surgery or refused surgery, and the provisional single-stent technique demonstrated better clinical outcomes than the double-stent approach.
K. N. O. Aljabry, Samir Taha Abeid, Y. A. Yasseen et al.· Research in Heart Yield and...· 0 citations
BACKGROUND
The prognostic relevance of the Academic Research Consortium-High Bleeding Risk (ARC-HBR) criteria in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is unknown.
OBJECTIVES
To assess the ARC-HBR criteria for predicting bleeding and adverse outcomes after CTO PCI.
METHODS
The author...
Sant Kumar, Anna V. Subramaniam, S. Thotakura et al.· American Journal of Cardiolo...· 1 citation
BACKGROUND
Percutaneous coronary intervention (PCI) is a widely available procedure for managing patients with and without acute myocardial infarction (AMI). Although age is a strong predictor of outcomes after PCI, contemporary data in patients with very advanced age are limited.
OBJECTIVES
The objectives of the stu...
Y. Saito, Yuichiro Mori, K. Yamaji et al.· JACC: Advances· 0 citations
Background: This study aimed to investigate the association between the prognostic nutritional index (PNI) and long-term all-cause mortality and major adverse cardiovascular events (MACEs) in elderly patients with chronic total occlusion (CTO) after successful percutaneous coronary intervention (PCI). Methods: This ret...
Ji-Quan Xiao, Song Wen, Ren-Shang Xu et al.· Journal of Cardiovascular De...· 0 citations
Among CCS patients diagnosed non-invasively, the medication-only group demonstrated comparable all-cause mortality and MI rates, but a significantly lower risk of revascularization compared with the PCI group, while incurring only onethird of the healthcare costs.
Hsien-Yuan Chang, Hsin-Yu Fang, Mu-Shiang Huang et al.· Journal of Food and Drug Ana...· 0 citations
Introduction Cangrelor is the only available intravenous P2Y12 inhibitor and is primarily used in patients with acute coronary syndromes (ACS), especially those presenting with cardiac arrest without prior oral P2Y12 therapy. Despite guideline recommendations and evidence from the CHAMPION trials, real-world data on it...
C. Beyer, M. Frick, Gabor Toth-Gayor et al.· Frontiers in Cardiovascular...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.